NL-OMON23245
Recruiting
Not Applicable
A 2-step phase I study evaluating the safety of (neo-)adjuvant cisplatin-pemetrexed and stereotactic radiotherapy (SRT) for patients with stage IB non-small-cell lung cancer (NSCLC).
prof. dr. EF Smit0 sites20 target enrollmentTBD
Conditionsnon-small-cell lung cancer. longkanker
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- non-small-cell lung cancer. longkanker
- Sponsor
- prof. dr. EF Smit
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Any histologically or cytologically proven NSCLC;
- •2\. Stage IB NSCLC (T2N0M0\);
Exclusion Criteria
- •1\. Pregnant or lactating women;
- •2\. Concomitant treatment with any other experimental drug under investigation;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A 2-step phase I study evaluating the safety of (neo-)adjuvant cisplatin-pemetrexed and stereotactic radiotherapy for patients with stage IB non-small-cell lung cancerlung cancerlung carcinoma10038666NL-OMON32798Vrije Universiteit Medisch Centrum20
Recruiting
Not Applicable
Study for intraoperative imaging of prostate cancer using OTL78NL-OMON21822On Target Laboratories, Inc39
Completed
Phase 1
Testing safety and efficacy of a live bacterial therapy for the treatment of Helicobacter pylori infectioHelicobacter pylori infectionInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12620000923965Servatus Ltd28
Active, not recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab plus Lenalidomide in Patients with Relapsed or Refractory Follicular LymphomaFollicular lymphomaMedDRA version: 19.0Level: LLTClassification code 10016904Term: Follicle centre lymphoma, follicular grade I, II, III NOSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-002467-42-FRF. Hoffmann-La Roche Ltd38
Active, not recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Atezolizumab plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination with Atezolizumab plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Diffuse large B-cell LymphomaFollicular Lymphoma (FL) or Diffuse Large B-cell Lymphoma (DLBCL)MedDRA version: 20.0Level: LLTClassification code 10016904Term: Follicle centre lymphoma, follicular grade I, II, III NOSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-004845-25-DEF. Hoffmann-La Roche Ltd.36